ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026

Garching / Munich, September 23, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that they will provide new data for Lu-edotreotide (ITM-11) in two poster presentations at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, held from September 26 – 30, 2026 in Boston, Massachusetts. One poster will feature Phase 3 COMPETE trial dosimetry results for 177Lu-edotreotide in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A second poster will highlight findings from a registry analysis of re-treatment with 177Lu-edotreotide in patients with progressive neuroendocrine tumors (NETs).

Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer

London, September 23, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Daniel Passeri, MSc, JD, as Chief Executive Officer (CEO). Mr. Passeri brings over 30 years of experience in oncology drug development, corporate strategy, and executive leadership, most recently serving as CEO of Cue Biopharma, where he led the company from inception into clinical development. Mr. Passeri succeeds Bo Rode Hansen, PhD, a member of Lift’s Board of Directors since 2023, who was appointed Interim CEO earlier this year during the search for a permanent CEO. Dr. Hansen will resume his role as a member of the Board of Directors and assume the role of President, where he will continue to leverage his deep corporate strategy and drug development experience to support the Company’s clinical development progress. LIfT Biosciences has been renamed Lift Therapeutics.

Graphene Market Driven by Advanced Composites, Electronics and Energy Storage

SNS Insider Estimates, the Graphene Market is projected to reach USD 12,407.3 million by 2035, growing at a 30.0% CAGR, while the U.S. market is projected to reach USD 3,044.3 million, advancing at 29.5% CAGR, as advanced materials adoption expands across electronics, batteries, composites, and energy applications.

SNS Insider Estimates, the Graphene Market is projected to reach USD 12,407.3 million by 2035, growing at a 30.0% CAGR, while the U.S. market is projected to reach USD 3,044.3 million, advancing at 29.5% CAGR, as advanced materials adoption expands across electronics, batteries, composites, and energy applications.

NIO and HERE Technologies expand European collaboration to support fresher maps and Navigation on Autopilot driving experiences

Amsterdam – HERE Technologies, the world’s leading mapping and location data company, and NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO), a leading company in the global smart electric vehicle market, today announced an expanded collaboration to advance intelligent navigation and future AI-driven driving experiences across Europe.

NIO and HERE Technologies expand European collaboration to support fresher maps and Navigation on Autopilot driving experiences

Amsterdam – HERE Technologies, the world’s leading mapping and location data company, and NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO), a leading company in the global smart electric vehicle market, today announced an expanded collaboration to advance intelligent navigation and future AI-driven driving experiences across Europe.

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)

Basel, 23 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function.5,6 Sefaxersen is a once-monthly subcutaneous injection designed to enable self-administration for people with IgAN. The safety and tolerability profile of sefaxersen was consistent with previously reported data, with no new safety signals identified.

Airwheel Wins European Product Design Award for AI Wheel Cabin 20 Inch Luxury Smart Scooter Carry on Hand Boarding Travel Electric Suitcase

BRUSSELS, BELGIUM, Sept. 23, 2026 (GLOBE NEWSWIRE) — Recently, Airwheel’s SE3SX Smart Rideable Cabin Suitcase has been recognized in the 2026 European Product Design Awards (EPDA), highlighting the company’s approach to integrating electric mobility, intelligent control, and luggage design into a single travel-oriented product. Listed in the Personal / Luggage: Carryon Suitcase category, the SE3SX reflects a design strategy that moves beyond conventional suitcase architecture to explore how luggage can become an active part of the travel experience.